Malcolm Moore

2.0k total citations · 1 hit paper
18 papers, 1.4k citations indexed

About

Malcolm Moore is a scholar working on Oncology, Surgery and Genetics. According to data from OpenAlex, Malcolm Moore has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Surgery and 3 papers in Genetics. Recurrent topics in Malcolm Moore's work include Pancreatic and Hepatic Oncology Research (6 papers), Testicular diseases and treatments (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Malcolm Moore is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), Testicular diseases and treatments (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Malcolm Moore collaborates with scholars based in Canada, United States and United Kingdom. Malcolm Moore's co-authors include Daniel J. Sargent, Stephen N. Thibodeau, Alberto Zaniboni, Stanley R. Hamilton, Geneviève Monges, Amy J. French, Steven Gallinger, Valter Torri, Frank Sinicrope and Silvia Marsoni and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Malcolm Moore

17 papers receiving 1.4k citations

Hit Papers

Defective Mismatch Repair As a Predictive Marker for Lack... 2010 2026 2015 2020 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
    2010 1.1k citations Daniel J. Sargent, Silvia Marsoni et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Malcolm Moore Canada 9 1.0k 912 298 270 210 18 1.4k
Ka Yeung Mark Wong Australia 11 1.7k 1.6× 780 0.9× 340 1.1× 340 1.3× 354 1.7× 17 1.9k
Michael D. Axelson United States 5 1.9k 1.8× 811 0.9× 376 1.3× 396 1.5× 399 1.9× 6 2.3k
Michael A. Morse United States 13 1.8k 1.7× 650 0.7× 365 1.2× 321 1.2× 432 2.1× 24 2.1k
Christina Therkildsen Denmark 15 516 0.5× 527 0.6× 293 1.0× 195 0.7× 171 0.8× 46 908
Paulo Fidalgo Portugal 19 778 0.7× 1.1k 1.2× 380 1.3× 374 1.4× 198 0.9× 45 1.6k
J. Lacava Argentina 13 630 0.6× 324 0.4× 304 1.0× 160 0.6× 186 0.9× 31 1.2k
E. Bourstyn France 12 503 0.5× 358 0.4× 637 2.1× 246 0.9× 124 0.6× 30 1.1k
Zacharenia Saridaki Greece 17 1.1k 1.1× 463 0.5× 349 1.2× 120 0.4× 370 1.8× 39 1.3k
Benjamin A. Weinberg United States 18 1.1k 1.1× 329 0.4× 315 1.1× 438 1.6× 450 2.1× 128 1.5k
Stefania Sciallero Italy 19 998 1.0× 617 0.7× 236 0.8× 252 0.9× 500 2.4× 59 1.3k

Countries citing papers authored by Malcolm Moore

Since Specialization
Citations

This map shows the geographic impact of Malcolm Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Moore more than expected).

Fields of papers citing papers by Malcolm Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Moore. The network helps show where Malcolm Moore may publish in the future.

Co-authorship network of co-authors of Malcolm Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm Moore. A scholar is included among the top collaborators of Malcolm Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm Moore. Malcolm Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Brenner, Andrew, Toral Patel, Ande Bao, et al.. (2025). Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial. Nature Communications. 16(1). 2079–2079. 7 indexed citations
2.
Cleary, Sean P., Laura A. Dawson, Elena Elimova, et al.. (2024). Vascular Resection for Pancreas Cancer – 10-year Experience from a Single High Volume-center. Annals of Surgery. 1 indexed citations
3.
Tempero, Margaret A., Dana B. Cardin, Andrew V. Biankin, et al.. (2015). Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT). Gastroenterology. 148(4). S–944. 1 indexed citations
4.
Nayan, Madhur, Michael A.S. Jewett, Lynn Anson‐Cartwright, et al.. (2015). MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS. The Journal of Urology. 193(4S). 1 indexed citations
5.
Lowery, Maeve A., David P. Kelsen, Malcolm Moore, et al.. (2015). Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. Journal of Clinical Oncology. 33(3_suppl). 358–358. 8 indexed citations
6.
Tabernero, Josep, Daniel D. Von Hoff, Malcolm Moore, et al.. (2013). Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: Influence of Prognostic Factors on Survival. Annals of Oncology. 24. iv11–iv12. 2 indexed citations
7.
Sargent, Daniel J., Silvia Marsoni, Geneviève Monges, et al.. (2010). Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology. 28(20). 3219–3226. 1114 indexed citations breakdown →
8.
Neoptolemos, John P., Markus W. Büchler, Deborah Stocken, et al.. (2009). ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. Journal of Clinical Oncology. 27(15_suppl). LBA4505–LBA4505. 46 indexed citations
9.
Kakiashvili, David, Lynn Anson‐Cartwright, Malcolm Moore, et al.. (2009). POST-CHEMOTHERAPHY RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR GERM CELL TUMORS: IS SURGERY INDICATED IN ALL AND IS BILATERAL TEMPLATE NECESSARY? PRINCESS MARGARET HOSPITAL EXPERIENCE. The Journal of Urology. 181(4S). 325–325. 6 indexed citations
10.
Kakiashvili, David, Lynn Anson‐Cartwright, Malcolm Moore, et al.. (2009). 944 POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR GERM CELL TUMOURS: IS SURGERY INDICATED IN ALL AND IS BILATERAL TEMPLATE NECESSARY?. European Urology Supplements. 8(4). 356–356.
11.
Jewett, Michael, Malcolm Moore, Padraig Warde, et al.. (2008). NON-RISK ADAPTED SURVEILLANCE IN STAGE I NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT): IMPROVED RECENT OUTCOMES. European Urology Supplements. 7(3). 85–85. 1 indexed citations
12.
Baetz, Tara, Elizabeth A. Eisenhauer, Lillian L. Siu, et al.. (2006). A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Investigational New Drugs. 25(3). 217–225. 25 indexed citations
13.
Warde, Padraig, Mary Gospodarowicz, Tony Panzarella, et al.. (2005). 719: Outcome in Stage I Seminoma Managed by Radiation Therapy and Surveillance. The Journal of Urology. 173(4S). 196–196. 1 indexed citations
14.
Rader, Janet S., D. Clarke-Pearson, Malcolm Moore, et al.. (2003). A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. Gynecologic Oncology. 91(2). 318–325. 9 indexed citations
15.
Collier, Jane, Brent W. Zanke, Malcolm Moore, et al.. (1999). No Association Between Hepatitis C and B–Cell Lymphoma. Hepatology. 29(4). 1259–1261. 93 indexed citations
16.
Moore, Malcolm, et al.. (1997). Clinical experience with gemcitabine in pancreatic carcinoma.. PubMed. 11(11). 1615–22; discussion 1622, 1625. 16 indexed citations
17.
Cody, Robert L., David Stewart, Malcolm Moore, et al.. (1993). Multicenter Phase II Study of Brequinar Sodium in Patients with Advanced Breast Cancer. American Journal of Clinical Oncology. 16(6). 526–528. 36 indexed citations
18.
Moore, Malcolm, Paul H. Murphy, & John A. Burdine. (1980). ECG-gated emission computed tomography of the cardiac blood pool.. Radiology. 134(1). 233–235. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ka Yeung Mark Wong Breakdown of academic impact, for papers by Michael D. Axelson Breakdown of academic impact, for papers by Michael A. Morse Breakdown of academic impact, for papers by Christina Therkildsen Breakdown of academic impact, for papers by Paulo Fidalgo Breakdown of academic impact, for papers by J. Lacava Breakdown of academic impact, for papers by E. Bourstyn Breakdown of academic impact, for papers by Zacharenia Saridaki Breakdown of academic impact, for papers by Benjamin A. Weinberg Breakdown of academic impact, for papers by Stefania Sciallero
Rankless by CCL
2026